Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis.

Yang, Xue-Gang; Sun, Yan-Yuan; Wang, Hai-Qing; Li, De-Shan; Xu, Guo-Hui; Huang, Xiao-Qi

Yang, Xue-Gang; Sun, Yan-Yuan; Wang, Hai-Qing; Li, De-Shan; Xu, Guo-Hui; Huang, Xiao-Qi.

Afiliación

Yang XG; Department of Interventional Radiology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu, China.
Sun YY; Huaxi MR Research Center (HMRRC), Functional and molecular imaging Key Laboratory of Sichuan Province, Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Wang HQ; Department of Interventional Radiology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu, China.
Li DS; Department of Hepato-Biliary-Pancreatic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu, China.
Xu GH; Department of Interventional Radiology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu, China.
Huang XQ; Department of Interventional Radiology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu, China.

Front Oncol ; 12: 914385, 2022.

Article en En | MEDLINE | ID: mdl-36176392

Palabras clave

PD-1 inhibitor; combined therapy; hepatocellular carcinoma; immune checkpoint inhibitor; sorafenib; transarterial chemoembolization

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google